Holly Hamner
Adult Health · Nampa, IDNPI 1366121824
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $828 and has fallen 65.4% since, to $286 in 2025.
Across 52 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$201
- Exact Sciences$187
- Amgen$132
- Gilead$112
- AstraZeneca$88
- Novo Nordisk$70
- plus $429 from 12 others
What the payments were for
- Food & beverage$1,219100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 7 | $201 |
| Exact Sciences | 9 | $187 |
| Amgen | 1 | $132 |
| Gilead | 1 | $112 |
| AstraZeneca | 6 | $88 |
| Novo Nordisk | 4 | $70 |
| Mylan Specialty L.p. | 4 | $61 |
| AbbVie | 3 | $55 |
| GSK | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $37 |
| Pfizer | 2 | $37 |
| Bayer | 2 | $33 |
| Johnson & Johnson | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,219 in reported general payments places this provider in the 70th percentile of 38 adult health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 30 | $28,202 |
| TrulicityDulaglutide | 18 | $19,633 |
| RexultiBrexpiprazole | 13 | $18,107 |
| EliquisApixaban | 19 | $12,010 |
| XareltoRivaroxaban | 14 | $9,624 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,085 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $2,621 |
| Atorvastatin Calcium | 83 | $1,031 |
| Omeprazole | 71 | $892 |
| Losartan Potassium | 67 | $847 |
| Metoprolol Succinate | 55 | $618 |
| Valsartan | 15 | $517 |
| Duloxetine Hcl | 19 | $487 |
| Levothyroxine Sodium | 64 | $454 |
| Hydroxyzine Hcl | 13 | $453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $70 | $28,20230 claims |
| Lilly USA, LLCTrulicity | $201 | $19,63318 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $13 | $18,10713 claims |
| PfizerEliquis | $37 | $12,01019 claims |
| Johnson & JohnsonXarelto | $24 | $9,62414 claims |
| AstraZenecaSymbicort | $88 | $4,08512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 38 adult health providers in Idaho.
Other adult health in Nampa
- Vanessa SchultzNampa$2K
- Tina ThorneNampa$193
- Michelle HicksBoise$40K
- Alisa OrrIdaho Falls$10K
- Tyson HarrisBlackfoot$8K
- Kaitlin HawsBoise$7K
- Jonelle HudsonBoise$6K
- Nicole BartlettTwin Falls$3K
- Leslie HassTwin Falls$2K
- Alla OsipchukCaldwell$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.